6月29日，药明生物盘中上涨3.39%，报34.28港元/股，成交额2.42亿港元。
消息面上，公司近期维持高频回购节奏，6月以来几乎每个交易日均进行场内回购，单日金额约5000万至1亿港元，6月10日获股东大会批准的回购授权上限约4.12亿股。此外，公司第25个原液生产厂于近日完成首批GMP生产且执行零偏差，产能持续扩张。行业层面，东方证券研报指出CXO行业景气高位运行，国内医疗健康一级市场前五月投融资总额同比增长57%，订单端量价双升。今日生命科学工具和服务板块多股走强，药明康德涨3.03%、康龙化成涨4.39%、药明合联涨2.55%、晶泰控股涨6.07%，板块共振效应显著。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.